List of Excipients in Branded Drug MEDICAL AIR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Norco Inc	MEDICAL AIR	oxygen	42602-004	NITROGEN
Keen Compressed Gas Co Inc	MEDICAL AIR	air	48273-007	NITROGEN
Keen Compressed Gas Co Inc	MEDICAL AIR	medical air	48273-012	NITROGEN
Strate Welding Supply Co Inc	MEDICAL AIR	air	49221-0025	NITROGEN

Medical Air Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Medical air is a medicinal gas, not a conventional pharmaceutical formulation. Its active product is purified atmospheric air, generally containing approximately 21% oxygen and 79% nitrogen. The commercial opportunity is concentrated in supply reliability, gas-generation systems, storage, delivery equipment, quality compliance, and integrated respiratory-care services rather than in excipient innovation or molecule-level patent protection.

What is medical air and how is it regulated?

Medical air is supplied for patient breathing, ventilation, anesthesia, respiratory therapy, and operation of medical devices. It is commonly produced by compressing and purifying atmospheric air or by blending purified oxygen and nitrogen.

In the United States, medical air is regulated as a medical gas and drug product. FDA requirements apply to production, processing, filling, labeling, storage, and distribution. Current good manufacturing practice requirements for medical gases are addressed in 21 C.F.R. Part 212, while general drug requirements remain relevant under the Federal Food, Drug, and Cosmetic Act and related regulations.[1]

Typical medical-air specifications

Attribute	Typical requirement or commercial target
Oxygen concentration	Approximately 20.4% to 21.4%, depending on applicable pharmacopoeia
Primary components	Oxygen and nitrogen
Physical state	Compressed gas
Administration	Medical gas pipeline, cylinder, compressor, ventilator, anesthesia system
Conventional excipients	None
Primary quality risks	Particulates, oil, water, carbon monoxide, carbon dioxide, hydrocarbons, microbial contamination
Regulatory category	Medicinal gas or drug, with device and facility interfaces

The exact specification depends on the governing pharmacopoeia, market, and product label. USP Medical Air and European Pharmacopoeia medical-air standards establish limits for identity, oxygen concentration, contaminants, and other quality attributes.[2,3]

Does medical air contain pharmaceutical excipients?

Medical air generally contains no added excipient. Oxygen and nitrogen are the intended gas components, and the product does not require a stabilizer, preservative, buffer, carrier, surfactant, or taste-masking agent.

The relevant excipient strategy is therefore an impurity-control and delivery-system strategy.

Why conventional excipients are unsuitable

Adding conventional excipients to inhaled medical air would create regulatory and clinical risks without a clear therapeutic benefit. Potential problems include:

• Altered oxygen concentration
• Toxic or irritant decomposition products
• Particulate generation
• Condensation or moisture accumulation
• Compatibility failures with ventilators and pipeline systems
• New inhalation toxicology requirements
• More complex validation and release testing

For this reason, medical-air manufacturers should avoid positioning humidity-control agents, antimicrobial additives, fragrances, oils, or other formulation materials as product excipients.

Functional substitutes for excipients

Commercially important adjuncts include:

• Heated humidifiers
• Heat-and-moisture exchangers
• Nebulizer interfaces
• Filters
• Drying systems
• Oxygen blenders
• Flow regulators
• Pressure regulators
• Gas analyzers
• Medical-air compressors
• Pipeline terminal units

These components are not excipients. They are devices, accessories, or facility systems that control the condition and delivery of the gas after manufacture.

What excipient strategy is appropriate for medical air?

A viable medical-air strategy should focus on four controls: gas purity, moisture management, material compatibility, and system validation.

Gas purity and contaminant control

The manufacturing process must control contaminants introduced by atmospheric intake, compressors, storage vessels, and distribution lines. The main technical risks are:

• Carbon monoxide from compressor exhaust or combustion sources
• Oil vapors from lubricated compressors
• Excess water vapor
• Carbon dioxide
• Volatile organic compounds
• Metallic or polymeric particulates
• Microbial contamination
• Cross-contamination from oxygen or other gases

Oil-free compressors can reduce hydrocarbon risk, but they do not eliminate the need for filtration, monitoring, preventive maintenance, and validated sampling.

Moisture management

Water is a major commercial and operational issue. Excess moisture can cause:

• Microbial growth
• Corrosion
• Frozen regulators
• Pipeline obstruction
• Sensor drift
• Condensation in ventilator circuits
• Inconsistent gas delivery

Drying systems, condensate management, dew-point monitoring, and validated pipeline maintenance are higher-value opportunities than adding a chemical excipient.

Material compatibility

Medical-air systems contact metals, elastomers, plastics, filters, seals, and tubing. Materials must be compatible with compressed gas, cleaning agents, pressure cycles, and expected humidity.

Although medical air has lower oxidation potential than pure oxygen, oxygen-compatible materials may still be required in systems that can switch between medical air and oxygen. Silicone, EPDM, PTFE, stainless steel, aluminum alloys, and engineering plastics may be selected based on pressure, temperature, sterilization, and chemical exposure.

Delivery-system validation

The final product delivered to the patient depends on the complete chain:

1. Air intake
2. Compressor or gas blender
3. Purification train
4. Receiver vessel
5. Pipeline or cylinder
6. Regulator
7. Ventilator or anesthesia machine
8. Patient circuit

A product specification that controls only the cylinder gas does not fully address risks created by the hospital pipeline or respiratory device. Integrated quality contracts and system qualification can create commercial differentiation.

What FDA regulatory status does medical air have?

Medical air is regulated as a medical gas and is subject to drug manufacturing and labeling requirements. FDA’s medical-gas framework includes requirements for current good manufacturing practice, facilities, equipment, quality control, and production records.[1,4]

FDA regulatory issues

Issue	Medical-air implication
New drug approval	Usually not the central pathway for standard compendial medical air
cGMP	Applies to production and filling
Medical-gas cGMP	Governed specifically under 21 C.F.R. Part 212
Labeling	Must identify gas, composition, intended use, warnings, and handling requirements
Drug establishment registration	Applies where the operation falls within FDA drug-establishment requirements
Device regulation	Applies separately to compressors, regulators, ventilators, humidifiers, and delivery equipment
Pharmacopoeial compliance	USP or other applicable compendial standards may apply
503B outsourcing	Relevant only in specific medical-gas outsourcing contexts

The gas and the delivery device are regulated through different legal frameworks. A company selling a medical-air generator may face both drug-quality obligations for the gas and device requirements for the generator or control system.

What patents protect medical air?

The basic composition of medical air is unlikely to support meaningful new composition-of-matter patent protection. Atmospheric air and a defined oxygen-nitrogen mixture are longstanding technologies. The commercial patent opportunity lies in manufacturing, purification, monitoring, distribution, and delivery.

Patentable technology areas

Potentially valuable claims may cover:

• Compressor architecture
• Oil-removal systems
• Molecular-sieve or membrane purification
• Moisture and carbon-dioxide removal
• Gas blending controls
• Oxygen-concentration monitoring
• Pressure-management systems
• Pipeline contamination detection
• Cylinder-filling systems
• Automated changeover systems
• Remote monitoring
• Predictive maintenance
• Fail-safe switching between medical air and oxygen
• Integrated humidification and ventilation systems
• Compact medical-air generators for hospitals or home care

These patents generally protect equipment or methods rather than the medical-air gas itself.

Patent-estate strength

Asset type	Expected patent strength	Commercial relevance
Medical-air composition	Low	Commodity product; limited exclusivity
Gas purification process	Moderate	Can protect operating cost and purity
Compressor design	Moderate to high	Relevant to installed systems and replacement cycles
Monitoring software	Moderate	May support service revenue but faces design-around risk
Pipeline safety system	Moderate	Can create hospital switching costs
Ventilator integration	Moderate to high	Stronger where hardware and software are combined
Humidification accessory	Moderate	Product differentiation and recurring consumables
Manufacturing know-how	High operational value	Often protected through trade secrets rather than patents

A company should not value a medical-air business on the assumption that its gas specification creates long-term market exclusivity. The defensible assets are installed infrastructure, validated processes, regulatory history, service contracts, and proprietary equipment.

When does medical air lose exclusivity?

Medical air does not have a conventional loss-of-exclusivity date comparable to a small-molecule drug with an NCE patent. The product is generally available from multiple industrial-gas suppliers and medical-gas manufacturers.

Exclusivity timeline

Milestone	Typical implication
Product specification established	No meaningful composition exclusivity
Facility qualification	Creates operational approval, not market exclusivity
Product or process patent grant	May protect equipment or manufacturing method
Patent expiration	Competitors may use the disclosed technical approach
Hospital installation	Creates customer retention and switching costs
Service contract renewal	Supports recurring revenue after product commoditization

Any patent expiration date must be assessed at the individual patent-family level. A medical-air manufacturer may have a portfolio of equipment, software, and process patents with different priority dates and terms. There is no single “medical air patent expiration date.”

Are there Paragraph IV challenges or Orange Book listings for medical air?

Standard medical air does not typically present the same Orange Book and Paragraph IV litigation profile as a branded tablet or injectable drug.

Orange Book status

The FDA Orange Book identifies approved drug products and patent or exclusivity information for eligible listed products.[5] Commodity medical air generally does not have a conventional Orange Book patent listing that creates a clear generic-entry barrier.

Paragraph IV risk

Paragraph IV litigation is principally associated with abbreviated new drug applications that challenge listed patents for reference-listed drugs. A standard medical-air product normally has limited exposure to that pathway because:

• The product is a medicinal gas rather than a conventional dosage-form drug.
• The principal barriers are manufacturing and facility compliance.
• The commercial product is often compendial.
• Device and infrastructure patents may be outside the conventional Orange Book framework.

Competitors can still face patent litigation involving compressors, purification systems, gas analyzers, ventilators, or humidification equipment. That litigation is more likely to be a direct patent dispute than a classic Paragraph IV case.

What commercial opportunities exist in medical air?

The strongest opportunities are linked to decentralized production, reliability, compliance, and recurring service revenue.

Hospital medical-air generation

Hospitals may use central medical-air plants instead of relying entirely on cylinders or bulk deliveries. Opportunities include:

• Modular compressor skids
• Redundant generator systems
• Automatic backup cylinders
• Remote purity monitoring
• Energy-efficient compressors
• Predictive maintenance
• Automated quality records
• Pipeline pressure monitoring

A generator can reduce cylinder handling and improve supply resilience, but it requires capital installation, validation, maintenance, and backup planning.

Medical-air-as-a-service

Suppliers can combine equipment, validation, maintenance, consumables, and monitoring under a subscription or long-term service agreement. Revenue can include:

• Equipment leasing
• Preventive maintenance
• Filter replacement
• Calibration
• Compliance testing
• Emergency supply
• Remote monitoring
• Staff training
• Documentation services

This model shifts competition from gas price to uptime, response time, and regulatory performance.

Respiratory-device integration

Medical air is essential to:

• Intensive-care ventilators
• Anesthesia machines
• Neonatal respiratory systems
• Noninvasive ventilation
• High-flow therapy systems
• Nebulizer systems
• Sleep-apnea devices
• Pulmonary-function testing equipment

Manufacturers that control validated interfaces between gas supply and respiratory equipment can capture higher margins than suppliers selling cylinders alone.

Home-care and decentralized care

Home medical air is more limited than hospital use because many home respiratory patients require oxygen rather than ordinary air. Opportunities are more plausible in:

• Portable respiratory equipment
• Home ventilation
• Home anesthesia or procedural systems
• Compact medical-air compressors
• Mobile clinics
• Ambulances
• Field hospitals
• Dental and outpatient facilities

The economics depend on noise, size, energy use, pressure stability, maintenance intervals, and alarm performance.

How does medical air compare with medical oxygen?

Medical oxygen has greater clinical differentiation and higher regulatory sensitivity. Medical air is generally a lower-cost carrier and breathing gas.

Factor	Medical air	Medical oxygen
Main composition	Approximately 21% oxygen, balance nitrogen	High-purity oxygen
Primary clinical role	Ventilation and breathing support without oxygen enrichment	Treatment of hypoxemia and oxygen-dependent conditions
Composition patentability	Very low	Very low
Supply economics	Often lower cost per unit	Higher value and tighter supply sensitivity
Combustion risk	Lower than oxygen	High
Main equipment opportunity	Compressors, purification, pipeline systems	Oxygen concentrators, liquefaction, storage, delivery
Generic-entry exposure	Limited conventional drug exclusivity	Limited conventional drug exclusivity
Key commercial differentiator	Reliability and purity	Purity, availability, flow, and delivery

Medical air should not be marketed as a substitute for therapeutic oxygen where oxygen enrichment is clinically indicated.

What manufacturing and IP barriers affect market entry?

The principal entry barriers are operational rather than molecular.

Manufacturing barriers

A new supplier must address:

• Qualified air intake location
• Compressor and dryer validation
• Filtration performance
• Contaminant testing
• Cylinder or pipeline filling controls
• Batch or lot traceability
• Calibration
• Change control
• Complaint handling
• Recall readiness
• Backup supply
• Pharmacopoeial testing
• Facility and equipment maintenance

Intellectual-property barriers

The most relevant IP diligence should cover:

1. Compressor patents
2. Purification and dryer patents
3. Gas-blending algorithms
4. Sensor calibration and monitoring
5. Pipeline safety systems
6. Hospital installation contracts
7. Software licenses
8. Third-party equipment interfaces
9. Trade secrets involving maintenance and validation
10. Freedom-to-operate for replacement filters and consumables

Trade-secret protection may be more important than patents for operating parameters, contamination-control procedures, maintenance schedules, and quality-release workflows.

Which companies compete in medical air?

Competition spans global industrial-gas companies, medical-gas specialists, hospital-equipment suppliers, and compressor manufacturers. Relevant commercial groups include Air Liquide, Linde, Messer, Nippon Sanso Holdings, Atlas Copco, Dräger, Getinge, Hamilton Medical, and other regional medical-gas and respiratory-equipment providers.

The competitive landscape differs by product:

• Bulk and cylinder supply: industrial-gas companies
• Hospital generators: medical-gas plant and compressor suppliers
• Ventilator integration: respiratory-device manufacturers
• Humidification and filters: respiratory consumables companies
• Monitoring: instrumentation and digital-health suppliers
• Maintenance: local technical-service providers

The most defensible commercial position often combines gas supply with equipment and service contracts.

Key Takeaways

• Medical air generally has no conventional pharmaceutical excipient.
• The product is primarily a purified oxygen-nitrogen gas mixture.
• The correct formulation strategy is impurity control, moisture management, and delivery-system compatibility.
• Standard medical air has little or no composition-based patent exclusivity.
• Orange Book and Paragraph IV risks are usually limited compared with conventional branded drugs.
• Patent value is concentrated in compressors, purification systems, monitoring, pipeline controls, and respiratory-device integration.
• Hospital generation systems and medical-air-as-a-service models offer stronger margins than commodity cylinder sales.
• FDA medical-gas cGMP requirements under 21 C.F.R. Part 212 are central to U.S. market entry.
• The main barriers are validated manufacturing, contamination control, supply reliability, facility qualification, and service capability.
• Commercial diligence should focus on installed infrastructure, recurring maintenance revenue, equipment patents, and freedom to operate.

FAQs

Is medical air the same as room air?

No. Medical air is manufactured, purified, tested, and supplied under medicinal-gas specifications. Room air has uncontrolled contamination, humidity, particulate, and microbial profiles.

Can water be added to medical air as an excipient?

Water should not be treated as an excipient in the gas product. Humidification is normally performed by a separate validated device in the respiratory circuit.

Does medical air require an ANDA?

A conventional ANDA and Paragraph IV strategy is generally not the central pathway for standard medical air. The applicable route depends on the product configuration, intended use, manufacturing operation, and jurisdiction.

Can a company patent a medical-air generator?

Yes. A company may patent compressor systems, purification trains, controls, monitoring methods, safety features, and integrated hospital systems. The gas composition itself is unlikely to provide meaningful new patent protection.

Is medical air commercially attractive for pharmaceutical companies?

The opportunity is usually stronger for industrial-gas, medical-device, facility-engineering, and service companies than for conventional pharmaceutical manufacturers. Pharmaceutical participation is most attractive where the company can monetize validated supply, hospital infrastructure, respiratory-device integration, or regulated medical-gas operations.

References

1. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, hazard analysis, and risk-based preventive controls for human food, and medical gases: 21 C.F.R. Part 212. U.S. Department of Health and Human Services.

2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Medical Air, USP monograph. United States Pharmacopeial Convention.

3. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Medicinal air, compressed. Council of Europe.

4. U.S. Food and Drug Administration. (2016). Medical gas containers and closures; current good manufacturing practice, certification, and other provisions. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Department of Health and Human Services.